EichorEICHOR
Study identifier: NCT06554301 Synced from ClinicalTrials.gov · August 02, 2026
● Recruiting

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension  ·  Sponsor: China National Center for Cardiovascular Diseases

PhasePhase 1
Planned participants72
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin. The main questions it aims to answer are: Based on standard treatment, does empagliflozin reduce pulmonary artery pressure and improve cardiac function in patients with pulmonary arterial hypertension? What medical problems do participants have when taking empagliflozin? Researchers will compare empagliflozin to a placebo (a look-alike substance that contains no drug) to see if empagliflozin works to treat patients with pulmonary arterial hypertension. Participants will: Take empagliflozin or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms and the drug taking situation

This description comes directly from the study's public registry record.

Talk to the study team

Tingting Guo, M.D  ·  +86 18610094559  ·  18610094559@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fuwai Hospital, Chinese Academy of Medical SciencesBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →